Comparison

iVisit vs MDOrb

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

iVisit

Connect with your healthcare provider through secure text messaging, video calls, and asynchronous question-based visits. This telemedicine solution facilitates efficient communication between patients and providers from your mobile device.

Highlights
  • Secure text messaging
  • Video visits
  • Asynchronous question-based visits
  • HIPAA compliant
  • Provider-patient communication
Features
Read full description

GenieMD iVisit makes connecting with your Provider quicker and easier from the convenience of your mobile device. iVisit offers a telemedicine solution that allows Providers and Patients to communicate more efficiently by using secure, HIPAA compliant text messaging, video visits and question-based asynchronous visits.

About

MDOrb

This platform connects private practitioners and care groups with a wider patient base. It aims to reduce overhead costs by allowing healthcare providers to focus on patient care.

Highlights
  • Expand patient reach
  • Cost-efficient
  • Focus on patient care
  • For private practitioners
  • For care groups
Features
Read full description

Physician Telehealth Platform App from MediOrbis Expand the patient reach If you are a private practitioner or a care group, MDOrb can help expand your patient base. Cost Efficient Minimize your overhead cost by just prioritizing patient need and care.

Screenshots

iVisit4 screens
MDOrb4 screens

Verdict

The call

The clearest difference is rating: iVisit at 4.5 against MDOrb's 2.8. iVisit also leads on ratings volume (65 vs 5) and iOS requirement (12.0 vs 16.6). MDOrb's advantage is ads (none vs shown) and monetization model (free vs ad-supported). On price, update cadence, in-app purchases and device support there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

ReceptionRating · Positive reviews · Number of ratings

iVisit holds the better App Store score, 4.5 against 2.8. That said, the two scores are not equally well evidenced: iVisit has 65 ratings behind it against 5, so its average is the more settled of the two.

UpkeepUpdate frequency

Both ship on a similar rhythm, roughly every 2 weeks. The most recent releases landed on October 8, 2026 and September 25, 2026 respectively.

Scorecard5 real differences · 5 level
iVisit versus MDOrb: the parameters behind the verdict, then further details
ParameteriVisitMDOrb
PriceFreeFree
Rating4.5 (65 ratings) — better2.8 (5 ratings)
Positive reviews85.2% of reviews—
Number of ratings65 — better5
Update frequencyEvery 2 weeksEvery 2 weeks
AdsYesNo — better
In-app purchasesNoNo
MonetizationAd-supportedFree — better
DevicesiPhone, iPad, iPod — betteriPhone, iPad
Requires iOS12.0 — better16.6
Further details — not scored
Size151 MB211 MB
Age rating17+17+
DeveloperGenieMD, Inc.
MediOrbis, LLC

Customer experience

iVisit

All ratings65 ratings
Positive89.2%
Neutral0.0%
Negative10.8%
Written reviews27 reviews
Positive85.2%
Neutral0.0%
Negative14.8%

MDOrb

All ratings5 ratings
Positive40.0%
Neutral0.0%
Negative60.0%

In-app purchases

None

iVisit

No in-app purchases

None

MDOrb

No in-app purchases

Questions

Is iVisit free?
iVisit is free to download, with no in-app purchases.
Is MDOrb free?
MDOrb is free to download, with no in-app purchases.
Which has better reviews, iVisit or MDOrb?
iVisit is rated higher. iVisit averages 4.5 out of 5 from 65 ratings, while MDOrb averages 2.8 from 5 ratings.
Do iVisit or MDOrb have ads?
iVisit shows ads; MDOrb does not.
Which is updated more often, iVisit or MDOrb?
iVisit ships an update every 2 weeks, and MDOrb every 2 weeks. Most recently, iVisit was updated on October 8, 2026 and MDOrb on September 25, 2026.

Other comparisons